Nath Bio-Genes Q4 FY26 Results: Revenue Surges 19% Driven by Strong Segment Growth and International JV

Nath Bio-Genes (India) Ltd. posted a robust 19% year-on-year revenue growth in Q4 FY26, reaching INR 4,316 million. This growth was driven by strong performance across its cotton, maize, and paddy segments.

The company's Uzbekistan joint venture made a significant debut contribution of INR 15 crores in its first operational year, showcasing its international expansion efforts.

Reader Takeaway: Revenue grew strongly with international expansion; high inventory and normalized margins are short-term points to watch.

Q4 FY26 Performance Highlights

Nath Bio-Genes reported total revenue of INR 4,316 million for the fourth quarter of FY26, a substantial 19% year-on-year increase. This follows a cumulative rise of 55% over the past five years.

Key segments showed strong performance: Cotton volume grew by 22.35% (13.8 lakh packets), Maize value surged by 78%, and Paddy volume increased by 25% with a 37% value growth.

An international milestone was achieved with the Uzbekistan joint venture contributing INR 15 crores in its first year. However, gross margins fell to 56% from 63% previously, mainly due to a change in product mix. Inventory increased to INR 4,446 million to support future growth.

During the conference call, management expects 15-20% revenue growth in FY27, with Cotton targeted at ~20% and Paddy at 20-25%. They indicated a preference for renting facilities instead of investing in new plants or storage, with minimal capital spending planned for land and vehicles.

Why This Matters

The reported growth shows Nath Bio-Genes' success in expanding market share and revenue, both at home and abroad. The Uzbekistan JV's immediate contribution signals a successful step in global diversification.

While margins normalizing from their highest point is a point to watch, management is confident about FY27 growth. Their strategy to counter risks like El Nino by diversifying geographically offers a positive outlook.

Background on JV

Nath Bio-Genes has been actively pursuing international expansion. The company incorporated a wholly-owned subsidiary in Uzbekistan in December 2022 specifically to establish a joint venture, which has now begun to yield financial results.

Following a careful approach to capital spending, management prefers renting facilities rather than investing heavily in plant and storage infrastructure. Future capital expenditure is expected to be minimal, primarily allocated for land and vehicles.

What This Means for Shareholders

Shareholders can look forward to stronger revenue streams, supported by solid domestic segment performance and international expansion. The company is set for scalable growth, aiming for a 15-20% revenue increase in FY27.

How well the company manages its inventory and stabilizes margins will be key for future profits.

Risks to Monitor

Inventory levels have risen to INR 4,446 million, leading to a negative cash flow of INR 13 crores and higher financing costs.

Gross margins have fallen from a very high 63% to a more sustainable 56%, due to a change in product mix.

External factors like China's export restrictions have hurt the Plant Nutrition segment by 18%. The El Nino weather pattern also remains an ongoing environmental risk.

Peer Comparison

Nath Bio-Genes' 19% revenue growth in Q4 FY26 shows strong momentum compared to some peers, depending on their individual segment performance. Its direct entry into an international JV provides a distinct advantage through diversification.

JK Agri Genetics Ltd. is a focused competitor in similar crop segments like maize and paddy, making its results a relevant benchmark. Rallis India Ltd., part of the Tata Group, offers broader industry context on agri-input sector trends and global strategy execution.

Key Figures

• Revenue for Q4 FY26: INR 4,316 million
• Year-on-year revenue growth in Q4 FY26: 19%
• Uzbekistan joint venture contribution in FY26: INR 15 crores
• Company inventory as of Q4 FY26: INR 4,446 million
• Cash flow in Q4 FY26: Negative INR 13 crores (due to inventory build)
• Management forecast for FY27 revenue growth: 15-20%

What to Track Next

Monitor how well the company liquidates its large inventory and manages the associated financing costs.

Track the performance and growth of the Uzbekistan JV and any future international ventures.

Assess the company's ability to meet its guided 15-20% revenue growth target for FY27.

Observe trends in EBITDA and PAT margins during FY27.

Evaluate how effectively management handles environmental risks like El Nino.

Watch for developments and launches of new products, such as the '2020' product.